Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.

Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM.

Cancer Manag Res. 2019 Dec 24;11:10777-10790. doi: 10.2147/CMAR.S212559. eCollection 2019. Review.

2.

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.

Roskoski R Jr.

Pharmacol Res. 2019 Dec 17;152:104609. doi: 10.1016/j.phrs.2019.104609. [Epub ahead of print] Review.

PMID:
31862477
3.

JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.

Venugopal S, Bar-Natan M, Mascarenhas JO.

Blood Rev. 2019 Oct 25:100634. doi: 10.1016/j.blre.2019.100634. [Epub ahead of print] Review.

PMID:
31677846
4.

Novel treatment strategies for myeloproliferative neoplasms.

Bose P, Masarova L, Verstovsek S.

Rinsho Ketsueki. 2019;60(9):1176-1185. doi: 10.11406/rinketsu.60.1176. Review.

PMID:
31597841
5.

Fedratinib: First Approval.

Blair HA.

Drugs. 2019 Oct;79(15):1719-1725. doi: 10.1007/s40265-019-01205-x. Review.

PMID:
31571162
6.

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.

Singer JW, Al-Fayoumi S, Taylor J, Velichko S, O'Mahony A.

PLoS One. 2019 Sep 27;14(9):e0222944. doi: 10.1371/journal.pone.0222944. eCollection 2019.

7.

Effects of leptin on norepinephrine in acute ischemic stroke.

Tao P, Jing Z, Shou-Hong G, Shu-Juan P, Jian-Peng J, Wen-Quan L, Wan-Sheng C.

Pharmazie. 2019 Aug 1;74(8):477-480. doi: 10.1691/ph.2019.9379.

PMID:
31526440
8.

Fedratinib Becomes New Option in Myelofibrosis.

[No authors listed]

Cancer Discov. 2019 Oct;9(10):1332. doi: 10.1158/2159-8290.CD-NB2019-102. Epub 2019 Aug 30.

PMID:
31471287
9.

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y.

Cancer Chemother Pharmacol. 2019 Oct;84(4):891-898. doi: 10.1007/s00280-019-03929-9. Epub 2019 Aug 23.

10.

TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis in vivo.

Akcora BÖ, Dathathri E, Ortiz-Perez A, Gabriël AV, Storm G, Prakash J, Bansal R.

FASEB J. 2019 Aug;33(8):9466-9475. doi: 10.1096/fj.201900215RR. Epub 2019 May 17.

PMID:
31100032
11.

New Concepts of Treatment for Patients with Myelofibrosis.

Bose P, Alfayez M, Verstovsek S.

Curr Treat Options Oncol. 2019 Jan 24;20(1):5. doi: 10.1007/s11864-019-0604-y. Review.

PMID:
30675650
12.

Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway.

Chen D, Zhang F, Wang J, He H, Duan S, Zhu R, Chen C, Yin L, Chen Y.

Front Pharmacol. 2018 Nov 13;9:1214. doi: 10.3389/fphar.2018.01214. eCollection 2018.

13.

Ezrin, a Membrane Cytoskeleton Cross-Linker Protein, as a Marker of Epithelial Damage in Asthma.

Jia M, Yan X, Jiang X, Wu Y, Xu J, Meng Y, Yang Y, Shan X, Zhang X, Mao S, Gu W, Pavlidis S, Barnes PJ, Adcock IM, Huang M, Yao X.

Am J Respir Crit Care Med. 2019 Feb 15;199(4):496-507. doi: 10.1164/rccm.201802-0373OC.

14.

Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.

Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Massefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, Becht K, Kim ND, McKeown MR, Roberts JM, Zhang J, Sim T, Alessi DR, Bradner JE, Lizcano JM, Blacklow SC, Qi J, Xu X, Gray NS.

ACS Chem Biol. 2018 Sep 21;13(9):2438-2448. doi: 10.1021/acschembio.7b00638. Epub 2018 Aug 31.

15.

RANKL-mediated osteoclastogenic differentiation of macrophages in the abdominal aorta of angiotensin II-infused apolipoprotein E knockout mice.

Tanaka T, Kelly M, Takei Y, Yamanouchi D.

J Vasc Surg. 2018 Dec;68(6S):48S-59S.e1. doi: 10.1016/j.jvs.2017.11.091. Epub 2018 Apr 21.

16.

The role of JAK2 inhibitors in MPNs 7 years after approval.

Passamonti F, Maffioli M.

Blood. 2018 May 31;131(22):2426-2435. doi: 10.1182/blood-2018-01-791491. Epub 2018 Apr 12.

PMID:
29650801
17.

JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers.

Pitroda SP, Stack ME, Liu GF, Song SS, Chen L, Liang H, Parekh AD, Huang X, Roach P, Posner MC, Weichselbaum RR, Khodarev NN.

Mol Cancer Ther. 2018 Apr;17(4):732-739. doi: 10.1158/1535-7163.MCT-17-0667. Epub 2018 Feb 21.

19.

Correction to "Interaction of 2,4-Diaminopyrimidine Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters".

[No authors listed]

Drug Metab Dispos. 2017 Nov;45(11):1146-1147. doi: 10.1124/dmd.116.073338err. No abstract available.

PMID:
28974558
20.

ETS transcription factor ELF5 induces lumen formation in a 3D model of mammary morphogenesis and its expression is inhibited by Jak2 inhibitor TG101348.

Chean J, Chen CJ, Shively JE.

Exp Cell Res. 2017 Oct 1;359(1):62-75. doi: 10.1016/j.yexcr.2017.08.008. Epub 2017 Aug 8.

PMID:
28800960

Supplemental Content

Loading ...
Support Center